Abstract 1499
Background
A risk stratification model using metabolic variables on PET/CT combined with other known prognostic factors has not been proposed. To evaluate the prognostic classification model for predicting tumor recurrence using metabolic parameters on F-18-FDG PET/CT, status of human papillomavirus (HPV) infection and known prognostic variables in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy (CCRT).
Methods
A total of 129 patients with cervical squamous cell carcinoma who underwent initial CCRT were eligible for this study. The clinical, pathological parameters, HPV status and metabolic parameters of pre-operative F-18 FDG PET/CT were used for analysis. Univariate and multivariate analysis for disease-free survival (DFS) were performed using traditional prognostic factors, metabolic parameters and HPV infection. Classification and regression decision tree (CART) was used to establish new classification.
Results
Among 129 patients, 29 patients (22.5%) had recurrence after a median follow-up of 60 months (range, 3–125 months). In univariate analysis, FIGO stage, tumor size, status of para-aortic lymph node metastasis, Nodal SUVmax, HPV positive were statistically significant in DFS. Multivariate analysis revealed that tumor size, paraaortic lymph node metastasis, nodal SUVmax and HPV infection status were independent prognostic factors. CART analysis classified the patients into three groups. First node was nodal SUVmax and HPV status was second node for patients with nodal SUVmax≤7.49 (p < 0.001); Group A (nodal SUVmax≤7.49 and HPV positive), group B (nodal SUVmax≤7.49 and HPV negative) and group C (nodal SUVmax>7.49). There was significant difference of DFS among 3 groups (p = 0.0012).
Conclusions
The present study revealed that the nodal SUVmax on F-18 FDG PET/CT and HPV infection status before CCRT are powerful an independent prognostic factor for the prediction of disease free survival in patients with cervical squamous cell carcinoma who underwent initial CCRT. Furthermore, simple prognostic classification model using nodal SUVmax and HPV infection status can provide classification of recurrence.
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2300 - AXL has a prognostic role in metastatic colorectal cancer (mCRC) and is a predictive biomarker of lack of efficacy of chemotherapy (CT) + cetuximab in RAS wild type (WT) patients (pts)
Presenter: Claudia Cardone
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2834 - Multimodal detection of homologous recombination repair gene mutations (HRRm) in a Phase II trial of olaparib plus abiraterone in metastatic castrate resistant prostate cancer (mCRPC)
Presenter: Thomas Carr
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3596 - Identification of a highly suppressive Treg subset associated to immunotherapy response
Presenter: Emilio Giunta
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3705 - A Novel Framework for Evaluating Biomarker Response Relationships in Immuno-oncology (IO)
Presenter: Jeffrey Evelhoch
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5332 - Comparison of OncoBEAM and NGS methods to detect plasma EGFR T790M mutations at progression of NSCLC
Presenter: Jessica Garcia
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5700 - Differential expression of PD-L1 and immune biomarkers by age: Decreased expression in pediatric/AYA patients with advanced cancer
Presenter: Omid Hamid
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
966 - Potential resistance mechanisms revealed primary resistance to crizotinib in ROS1+ non-small-cell lung cancer using next generation sequencing: A multicenter study
Presenter: Quxia Zhang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2171 - Prevalence of CLDN18.2, HER2, and PD-L1 in Gastric Cancer Samples
Presenter: Diarmuid Moran
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2318 - Epigenetic markers in circulating cell-free DNA for detection of early stage colorectal cancer
Presenter: Yanqun Liu
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3625 - Detection and clearance of RET variants in plasma cell free DNA (cfDNA) from patients (pts) treated with LOXO-292
Presenter: Benjamin Besse
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract